BRPI0509085A - processo de neuroproteção através da inibição farmacológica da proteìna quinase ativada por amp - Google Patents
processo de neuroproteção através da inibição farmacológica da proteìna quinase ativada por ampInfo
- Publication number
- BRPI0509085A BRPI0509085A BRPI0509085-7A BRPI0509085A BRPI0509085A BR PI0509085 A BRPI0509085 A BR PI0509085A BR PI0509085 A BRPI0509085 A BR PI0509085A BR PI0509085 A BRPI0509085 A BR PI0509085A
- Authority
- BR
- Brazil
- Prior art keywords
- neuroprotection
- protein kinase
- activated protein
- neurons
- pharmacological inhibition
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 230000004112 neuroprotection Effects 0.000 title abstract 3
- 230000009038 pharmacological inhibition Effects 0.000 title abstract 2
- 102000001253 Protein Kinase Human genes 0.000 title 1
- 108060006633 protein kinase Proteins 0.000 title 1
- 210000002569 neuron Anatomy 0.000 abstract 3
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 abstract 2
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 108010011376 AMP-Activated Protein Kinases Proteins 0.000 abstract 1
- 102000014156 AMP-Activated Protein Kinases Human genes 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 210000005013 brain tissue Anatomy 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55600004P | 2004-03-24 | 2004-03-24 | |
| PCT/US2005/009797 WO2005092068A2 (en) | 2004-03-24 | 2005-03-23 | Novel method of neuroprotection by pharmacological inhibition of amp-activated protein kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0509085A true BRPI0509085A (pt) | 2007-08-21 |
Family
ID=35056772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0509085-7A BRPI0509085A (pt) | 2004-03-24 | 2005-03-23 | processo de neuroproteção através da inibição farmacológica da proteìna quinase ativada por amp |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8293791B2 (enExample) |
| EP (1) | EP1734973A4 (enExample) |
| JP (1) | JP2008504228A (enExample) |
| KR (2) | KR101283416B1 (enExample) |
| CN (1) | CN101132802A (enExample) |
| AU (1) | AU2005226731A1 (enExample) |
| BR (1) | BRPI0509085A (enExample) |
| CA (1) | CA2560843A1 (enExample) |
| IL (1) | IL178242A0 (enExample) |
| MX (1) | MXPA06010916A (enExample) |
| WO (1) | WO2005092068A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008504228A (ja) | 2004-03-24 | 2008-02-14 | ファスジェン・リミテッド・ライアビリティ・カンパニー | Ａｍｐ活性化プロテインキナーゼの薬理学的阻害による新規神経保護方法 |
| WO2014160989A2 (en) | 2013-03-28 | 2014-10-02 | The Trustees Of Columbia University In The City Of New York | Reperfusion with omega-3 glycerides promotes donor organ protection for transplantation |
| KR101152607B1 (ko) | 2005-12-20 | 2012-06-05 | 에스케이케미칼주식회사 | ６-[４-(２-피페리딘-1-일-에톡시)-페닐]-３-피리딘-４-일-피라졸로[１,５-ａ]피리미딘의 제조방법 |
| CA2749884C (en) | 2009-01-28 | 2018-01-23 | Cara Therapeutics, Inc. | Bicyclic pyrazolo-heterocycles |
| US7741350B1 (en) * | 2009-01-28 | 2010-06-22 | Cara Therapeutics, Inc. | Bicyclic pyrazolo-heterocycles |
| KR101532211B1 (ko) * | 2014-04-30 | 2015-06-30 | 세종대학교산학협력단 | Ampk 억제기능에 기반한 뇌졸중 치료용 약학적 조성물 및 방법 |
| CN119868551A (zh) * | 2024-11-28 | 2025-04-25 | 四川大学华西医院 | F-box蛋白48的抑制剂的新用途和治疗缺血性脑血管病的药物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9602080D0 (en) * | 1996-02-02 | 1996-04-03 | Pfizer Ltd | Pharmaceutical compounds |
| US5981575A (en) | 1996-11-15 | 1999-11-09 | Johns Hopkins University, The | Inhibition of fatty acid synthase as a means to reduce adipocyte mass |
| CO5180581A1 (es) | 1999-09-30 | 2002-07-30 | Pfizer Prod Inc | Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia |
| IL147696A0 (en) * | 2001-01-25 | 2002-08-14 | Pfizer Prod Inc | Combination therapy |
| US6423705B1 (en) * | 2001-01-25 | 2002-07-23 | Pfizer Inc. | Combination therapy |
| JP2008504228A (ja) | 2004-03-24 | 2008-02-14 | ファスジェン・リミテッド・ライアビリティ・カンパニー | Ａｍｐ活性化プロテインキナーゼの薬理学的阻害による新規神経保護方法 |
-
2005
- 2005-03-23 JP JP2007505165A patent/JP2008504228A/ja active Pending
- 2005-03-23 CN CNA2005800127675A patent/CN101132802A/zh active Pending
- 2005-03-23 AU AU2005226731A patent/AU2005226731A1/en not_active Abandoned
- 2005-03-23 BR BRPI0509085-7A patent/BRPI0509085A/pt not_active IP Right Cessation
- 2005-03-23 MX MXPA06010916A patent/MXPA06010916A/es not_active Application Discontinuation
- 2005-03-23 KR KR1020127016911A patent/KR101283416B1/ko not_active Expired - Fee Related
- 2005-03-23 US US10/593,710 patent/US8293791B2/en not_active Expired - Fee Related
- 2005-03-23 CA CA002560843A patent/CA2560843A1/en not_active Abandoned
- 2005-03-23 WO PCT/US2005/009797 patent/WO2005092068A2/en not_active Ceased
- 2005-03-23 KR KR1020067022076A patent/KR20070085093A/ko not_active Ceased
- 2005-03-23 EP EP05732234A patent/EP1734973A4/en not_active Withdrawn
-
2006
- 2006-09-21 IL IL178242A patent/IL178242A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL178242A0 (en) | 2007-03-08 |
| CA2560843A1 (en) | 2005-10-06 |
| EP1734973A2 (en) | 2006-12-27 |
| EP1734973A4 (en) | 2010-08-04 |
| WO2005092068A3 (en) | 2007-09-20 |
| JP2008504228A (ja) | 2008-02-14 |
| KR20120078756A (ko) | 2012-07-10 |
| MXPA06010916A (es) | 2007-07-25 |
| CN101132802A (zh) | 2008-02-27 |
| AU2005226731A1 (en) | 2005-10-06 |
| KR101283416B1 (ko) | 2013-07-08 |
| KR20070085093A (ko) | 2007-08-27 |
| US20090137665A1 (en) | 2009-05-28 |
| US8293791B2 (en) | 2012-10-23 |
| WO2005092068A2 (en) | 2005-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rigopoulos et al. | Acute and chronic paronychia | |
| Garibyan et al. | Advanced aging skin and itch: addressing an unmet need | |
| Jafferany et al. | Geriatric dermatoses: a clinical review of skin diseases in an aging population | |
| Boulton et al. | Whither pathogenetic treatments for diabetic polyneuropathy? | |
| Mulhem et al. | Treatment of nongenital cutaneous warts | |
| Schaefer et al. | A randomized, controlled, double-blind, multi-center trial to evaluate the efficacy and safety of a liquid containing ivy leaves dry extract (EA 575®) vs. placebo in the treatment of adults with acute cough | |
| BRPI0710085B8 (pt) | composições oftálmicas e seus kits | |
| WO2007014323A3 (en) | Use of heat shock to treat ocular disease | |
| BRPI0517485A (pt) | composto, composição farmacêutica, método de tratamento de doença em mamìferos, método de aumento da atividade de receptor colinérgico, método de tratamento, prevenção ou alìvio dos sintomas associados a disfunção em mamìfero e/ao aumento da pressão intraocular ou glaucoma | |
| Huang et al. | A comparative study: superficial shaving combined with photodynamic therapy versus cryotherapy in the treatment of recalcitrant plantar warts | |
| BRPI0509085A (pt) | processo de neuroproteção através da inibição farmacológica da proteìna quinase ativada por amp | |
| Hauschild et al. | Effective photodynamic therapy of actinic keratoses on the head and face with a novel, self‐adhesive 5‐aminolaevulinic acid patch | |
| Borroni et al. | Risk of acute postoperative hypertension after topical photodynamic therapy for non‐melanoma skin cancer | |
| Attia et al. | Report: Cutaneous disorders in uremic patients on hemodialysis: an Egyptian case‐controlled study | |
| Stebbins et al. | MAL‐PDT for difficult to treat nonmelanoma skin cancer | |
| BRPI0510286A (pt) | composiçaõ antifúngica para aplicação tópica na pele ou nas unhas, e, uso de um composto antfúngico de alil-amina | |
| WO2010078419A3 (en) | Herbal-based nasal solution and method of use thereof | |
| Lee et al. | A double-blind, randomised, placebo-controlled trial of EMLA® cream (eutectic lidocaine/prilocaine cream) for analgesia prior to cryotherapy of plantar warts in adults | |
| Miller et al. | Factors related to pain during routine photodynamic therapy: a descriptive study of 301 patients | |
| Yin et al. | Pulsed dye laser for the treatment of nail psoriasis | |
| CN102949502B (zh) | 一种治疗头皮毛囊炎的外用中药 | |
| Flowers | Imiquimod in the treatment of actinic keratoses and other intraepithelial neoplasms. | |
| Muhaidat et al. | Comparison of the efficacy and safety of two cryotherapy protocols in the treatment of common viral warts: a prospective observational study | |
| Prakoeswa et al. | Glove‐Induced Hand Dermatitis: A Study in Healthcare Workers during COVID‐19 Pandemic in Indonesia | |
| BR0316973A (pt) | Uso de ácido docosahexanóico como substância ativa para o tratamento de lipodistrofia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |